2010
Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness
Yazdanpanah Y, Sloan CE, Charlois-Ou C, Le Vu S, Semaille C, Costagliola D, Pillonel J, Poullié AI, Scemama O, Deuffic-Burban S, Losina E, Walensky RP, Freedberg KA, Paltiel AD. Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness. PLOS ONE 2010, 5: e13132. PMID: 20976112, PMCID: PMC2956760, DOI: 10.1371/journal.pone.0013132.Peer-Reviewed Original ResearchConceptsQuality-adjusted life monthsCost-effectiveness ratioQuality-adjusted life yearsGeneral populationRoutine HIVHIV prevalenceFrequent screeningLife expectancyAnnual HIV incidenceRoutine HIV screeningUndiagnosed HIV prevalenceHigh-risk groupHIV testing behaviorsInjection drug usersFrench general populationEpidemiology of infectionHIV screeningVoluntary HIVHIV infectionHIV testingAnnual screeningHIV incidenceMean ageHIV screenClinical impact
2005
Expanded Screening for HIV in the United States — An Analysis of Cost-Effectiveness
Paltiel AD, Weinstein MC, Kimmel AD, Seage GR, Losina E, Zhang H, Freedberg KA, Walensky RP. Expanded Screening for HIV in the United States — An Analysis of Cost-Effectiveness. New England Journal Of Medicine 2005, 352: 586-595. PMID: 15703423, DOI: 10.1056/nejmsa042088.Peer-Reviewed Original ResearchConceptsOne-time screeningEnzyme-linked immunosorbent assayGeneral populationHuman immunodeficiency virus (HIV) infectionRoutine HIV counselingEffective antiretroviral therapyImmunodeficiency virus infectionLow-risk populationHigh-risk populationQuality-adjusted survivalCost-effectiveness ratioU.S. general populationAverage survival timeCDC thresholdAntiretroviral therapyHIV screeningHIV antibodiesObservational cohortHIV counselingClinical trialsCost-effectiveness groundsVirus infectionEarly diagnosisVoluntary screeningSurvival time